Navigation Links
Multimodal Treatment of Peritoneal Metastases Offers Hope for Many Patients With Colorectal Cancer
Date:11/1/2012

BERLIN, November 1, 2012 /PRNewswire/ --

8th World Congress on Peritoneal Surface Malignancies

At the 8th World Congress on Peritoneal Surface Malignancies held from October 30 to November 2 in Berlin, Germany, a paradigm shift was emphasized that offers hope to numerous cancer patients worldwide. So far patients with peritoneal metastases of solid tumors in the abdominal region were considered not to be candidates for curative treatment. These patients had an extremely poor prognosis and were treated solely with systemic chemotherapy within the framework of "best supportive care."

At the international congress definitive data was presented sharing that multimodal treatment of peritoneal metastases of colorectal cancer can be a promising approach and is associated with a five-year survival of up to 30-50%. Dr. Paul Sugarbaker (Washington, DC, USA), surgeon and congress president, is considered a pioneer of this approach which uses a combination of cytoreductive surgery (CRS), hyperthermic intraperitoneal chemotherapy (HIPEC) and subsequent systemic chemotherapy. With HIPEC the chemotherapeutic agent is distributed in the abdominal region at 42°C for about 60 to 90 minutes. "The residual tumor tissue is exposed to a multiple of the normal concentration of the cytotoxic agent that is administered during conventional chemotherapy," explained Sugarbaker. "This is why the method is successful. In selected patients it can double the survival time - and should therefore be considered as a therapeutic option within an individualized treatment approach".

The aspect of individualized treatment is important, because the method is suitable only for patients with isolated and limited peritoneal carcinomatosis without metastases outside the abdomen. "However, this group constitutes up to 15% of all patients with colorectal cancer after all," pointed out Dr. Prof. Pompiliu Piso (Regensburg, Germany), co-president of the congress. "In simple terms this means that in Germany, for example, where there are 70,000 new cases of colon cancer each year, the prognosis of around 10,000 patients could be substantially improved by the use of this method."

Further information

http://www.peritonealconference2012.com

http://www.dgav.de

Press contact
Dr. Bettina Albers
albers@albersconcept.de
Tel. + 49-174-2165629


'/>"/>
SOURCE 8th World Congress on Peritoneal Surface Malignancies
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. ViThera Novel Approach Using Probiotics to Deliver Elafin Shows Promise as a Future Inflammatory Bowel Disease (IBD) Treatment
2. Ebola antibody treatment, produced in plants, protects monkeys from lethal disease
3. QIAGEN and Bayer HealthCare Partner to Develop Companion Diagnostics to Guide Treatment Decisions for Targeted Cancer Therapies
4. Pro Bono Bio Announces the Successful Development of Subcutaneous and Long-Acting Blood Factors VIIa,VIII and IX for the Treatment of Haemophilia
5. Preclinical data shows 100 percent prevention and treatment of influenza with engineered human antibody
6. Walgreens Joins with Ferring Pharmaceuticals Inc. to Offer Products and Resources to Women Facing Fertility Complications from Cancer Treatment
7. First Evidence that Adipose Stem Cell-Based Critical Limb Ischemia Treatment is Safe & Effective is published in Circulation Journal by Lead Investigator Dr. Han Cheol Lee of Pusan National University
8. ARMGO Pharma, Inc. announces data which supports its Rycal program as a novel approach for the treatment of stress-induced cognitive disorders
9. CTBE (Brazil) to Acquire Equipment for Biomass Pretreatment Research
10. Lightlake Therapeutics Inc. Announces Positive Final Phase II Clinical Trial Results of Binge Eating Disorder Treatment
11. Elusys Awarded Additional $50.2 Million Under An Exisiting U.S. Government Contract To Support Final Stages Of Development Of ETI-204, For Treatment Of Inhalational Anthrax
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/19/2017)... Ca (PRWEB) , ... April 18, 2017 , ... A ... technological advances. This webinar, which is part of the Protein and Cell Analysis ... Cytometer and outline where this technology fits in current and future applications. , ...
(Date:4/19/2017)... ... ... Nobilis Therapeutics Announces Completion of Landmark NBTX-001 Clinical Trial in 81 ... Post Traumatic Stress Disorder Trial , Nobilis Therapeutics, Inc. announced today the ... NBTX-001, a xenon-based therapeutic in the treatment of Panic Disorder. , Panic ...
(Date:4/19/2017)... ... April 19, 2017 , ... As part ... webinars accessible to novices as well as experienced users, attendees will gain a ... coagulation screening tests. , Hemostasis testing quality is determined by preanalytical variables ...
(Date:4/19/2017)... and WESTMINSTER, Colo. , ... ("Oxford"), an industry-leading specialty finance firm that provides ... companies, today announced the closing of a $20 ... ("Cerapedics") a privately-held orthobiologics company engaged in the ... for the treatment of orthopedic injuries. ...
Breaking Biology Technology:
(Date:3/13/2017)... Future of security: Biometric Face Matching software  ... ... enables to match face pictures against each other or against large databases. The ... ... fastest software for biometric Face Matching on the market. The speed is at ...
(Date:3/7/2017)... BRIGHTON, England , March 7, 2017 Brandwatch ... been chosen by The Prince,s Trust to uncover insights ... insights across The Trust. The UK,s leading youth charity ... track social campaign results and get a better understanding of the ... ...
(Date:3/2/2017)... , March 2, 2017 Summary This ... Perrigo and its partnering interests and activities since 2010. ... Read the ... and Alliance since 2010 report provides an in-depth insight into ... sciences companies. On demand company reports are prepared ...
Breaking Biology News(10 mins):